MAP2K7 and gastric cancer: A phase II selumetinib/docetaxel trial is currently ongoing for second-line metastatic GC patients as part of an umbrella trial with patient selection based on high vs low MEK signature or RAS gene alterations (clinicaltrials.gov NCT#02448290).